BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies (NASDAQ: BSGM) announced the appointment of Edwin Wang to its Advisory Board on March 27, 2023. Wang brings over 20 years of experience in private equity and venture capital, having founded Accretive Capital Partners LLC, which raised a top-quartile secondary direct investment fund. He previously directed the restructuring of a $1 billion venture capital portfolio at Asymmetry Capital LLC. His expertise is expected to enhance BioSig's capital markets strategy. BioSig's PURE EP™ System is gaining traction in the electrophysiology market, which is projected to reach $16 billion by 2028, aiming to improve patient outcomes and reduce healthcare costs.

BioSig Technologies, Inc. (NASDAQ: BSGM) has appointed Lorraine Spurge to its Advisory Board to enhance business development and access to capital. Ms. Spurge has a 40-year history in finance, having helped raise over $200 billion for growth companies. Her experience includes roles at Drexel Burnham Lambert and various entrepreneurial ventures. BioSig aims to leverage her expertise as it seeks to expand its shareholder base and advance growth initiatives. The company’s PURE EP™ System, an FDA-cleared device for cardiac procedures, is seeing commercial launch in prominent healthcare facilities, with a projected growth rate for the electrophysiology market at 11.2% by 2028.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced it holds no cash or accounts at Silicon Valley Bank and has no business relationship with the bank. The company's PURE EP™ System, approved by the FDA, enhances cardiac signal visualization, making procedures more efficient. This system is being adopted by major healthcare institutions like Mayo Clinic and Cleveland Clinic. A recent study found that electrophysiologists rated the PURE EP™ System as equivalent or superior to conventional systems for 93.6% of signal samples. The global electrophysiology market is projected to reach $16 billion by 2028, growing at 11.2% annually.

BioSig Technologies (NASDAQ: BSGM) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock price closed above $1.00 for 10 consecutive business days from February 6 to February 17, 2023. Additionally, BioSig received confirmation of compliance with the market value of listed securities, maintaining a value of $35 million or greater for 11 consecutive days from January 31 to February 17, 2023. Both compliance issues have been resolved, according to Nasdaq. BioSig's PURE EP™ System is enhancing signal visualization capabilities in electrophysiology, contributing to improved patient care.

BioSig Technologies (NASDAQ: BSGM) has announced the issuance of a new utility patent, No. 11,569,853, for its innovative PURE EP™ universal notch filtering technology. This technology enables the removal of fixed frequency interference from intracardiac signals, preserving critical data without introducing artifacts. Following this patent, the company now holds 56 worldwide patents in digital signal processing, with 11 U.S. applications pending. The PURE EP™ System is now commercially launched and shows promise in enhancing electrophysiology procedures. Recent studies indicate a high performance rating for PURE EP™ compared to conventional systems.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the retirement of CFO Steve Chaussy after 12 years, appointing Steve Buhaly as his successor. Buhaly has over 15 years of experience in public companies, including a significant role at Qorvo, contributing to its growth to an $11 billion market cap. Chaussy played a pivotal role in foundation-building for BioSig, while Buhaly's background in corporate finance and technology positions him well to support the commercial rollout of the PURE EP™ System. This transition comes as the company focuses on expanding its market presence in a projected $16 billion electrophysiology market by 2028.

BioSig Technologies, Inc. (BSGM) announced significant milestones and developments as of January 2023. The FDA 510(k)-cleared PURE EP™ System has been utilized in approximately 3,000 cases nationwide. The company is optimistic about multiple sales closings and new clinical data expected in the first half of 2023. Despite a challenging economic climate in 2022, BioSig raised $3.8 million in private placements and received an extension from Nasdaq to regain compliance with equity requirements until May 22, 2023. The global electrophysiology market is projected to reach $16 billion by 2028, indicating a promising future for BioSig's innovative technology.